Navigation Links
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Date:4/11/2008

TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Targeting mutant p53 protein and tumor vasculature: An effective

combination therapy for advanced breast tumors" (Abstract #2341, New

Targets 1: Mechanisms Session) - Poster session scheduled for Monday,

April 14, 2008 from 8:00 am to 12:00 pm.

-- "An immunocytokine that binds to phosphatidylserine generates an

effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor

Vaccines Session) - Poster session scheduled for Monday, April 14,

2008 from 1:00 pm to 5:00 pm.

-- "Combination of a monoclonal anti-phosphatidylserine antibody with

docetaxel strongly inhibits the growth and metastasis of

hormone-refractory prostate cancers in mice" (Abstract #2551, New

Approaches to Biological Therapy Session) - Oral presentation

scheduled for Monday, April 14, 2008 at 2:10 pm.

-- "Antibody targeting of phosphatidylserine produces a cytokine

microenvironment that enhances innate anti-tumor immune responses"

(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 from

8:00 am to 12:00 pm.

Abstracts and information abou
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
2. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
3. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
8. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., Dec. 1 Reportlinker.com announce...n its catalogue: ,, Chromium - Global Market ...94/Chromium---Global-Market-Trends.html ,, Wor... by stainless steel, while growth in aerospace and...for growth of chromium metal. Environmental constr...
(Date:12/1/2009)..., Dec. 1 Reportlinker.com announce...n its catalogue: ,, Emerging Clinical Trial Lo...changing healthcare and regulatory environment ,...-Clinical-Trial-Locations---Eastern-Europe-Market-...y-environment.html ,, Over the last decade pha...
(Date:12/1/2009)...GE, Mass., Dec. 1 To address the e...promote its potential, a group of individuals and ... Biology Industry Association (SynBIA) in Cambridg...ation is to provide a forum for individuals and co...dress its opportunities and its challenges, and ad...
(Date:12/1/2009)... Dec. 1 /PRNewswire-Asia/ -- Shanghai ChemPartner,...ing China-based Contract Research,Organization (CR...oitte,Technology Fast 50 China, ranking 3rd on the...n China. The award is a testament to ChemPartner,s...o 2008. , The results of the 2009 Deloitt...
Breaking Biology Technology:Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3
...TON, N.H., May 21 The American Acne & Rosacea...nt of National Acne Awareness Month which will occ...AARS, James Q. Del Rosso, DO, President, stated th...pportunity to educate healthcare providers concern...s for this disease which affects over 17 million A...
...ersal Definition of Myocardial Infarction provided...ties , , TOKYO and INDIANAPOLIS, May 21 Investig...ied the new classification system for the Universa...ts of the study and showed that patients with acut... coronary intervention (PCI) and taking prasugrel,...
...oved for peripheral neuropathic pain in non-diabet...X, Inc. (Nasdaq: NGSX ), a biopharmaceutical com...el pain management therapies, announced today that...eting authorization of Qutenza(TM) 179 mg cutaneou...eripheral neuropathic pain in non-diabetic adults ...
Other Biology Technology:American Acne & Rosacea Society Announces Acne Awareness Month - June 2009 2Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 2Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 3Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 4Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 5Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 6NeurogesX Receives European Commission Approval for Qutenza(TM) 2NeurogesX Receives European Commission Approval for Qutenza(TM) 3NeurogesX Receives European Commission Approval for Qutenza(TM) 4NeurogesX Receives European Commission Approval for Qutenza(TM) 5
(Date:12/2/2009)...urance of a cancer-free status did not prompt peop...raphy (CT) lung-cancer screening program to pick u...tudy published in Cancer Epidemiology, Biomarkers...ion for Cancer Research. The December issue contai...should negate widespread concern in the lung scree...
(Date:12/2/2009)...e University Medical Center researchers have figur...r glioma may be better able to resist radiation th...aling pathway in these cancer stem cells, they wer...on in a laboratory experiment. , The work build...em cells resist the effects of radiation much bett...
(Date:12/2/2009)...reporting the first identification of substances i... changes harmless marine bacteria into killers tha...ACS, Environmental Science & Technology , a semi-...te that bleaching already has destroyed up to 30 p...are searching for ways to slow or stop the damage....
Breaking Biology News(10 mins):Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Discovery makes brain tumor cells more responsive to radiation 2Big Top Cupcake 28TM 29 Brand Awarded With Guinness World Record For Worlds Largest Cupcake 59088 1Big Top Cupcake 28TM 29 Brand Awarded With Guinness World Record For Worlds Largest Cupcake 59088 2National Health Care Reformers Should Pay Attention to Lawsuit Alleging that Nations Largest Insurer Routinely Denies Liver Transplants 59086 1National Health Care Reformers Should Pay Attention to Lawsuit Alleging that Nations Largest Insurer Routinely Denies Liver Transplants 59086 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 1BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 3
...logy have developed a prosthetic vein valve to hel...ition known as chronic venous insufficiency. The c...ople in the United States alone, occurs when valve...ay flow of blood back to the heart. , "Blood fl...ses vein valves to pump blood in one direction bac...
...ORTCNCIAACR Symposium on "Molecular Targets and Ca...Palexpo, Geneva] from Tuesday 21 October-Friday 24...adline for booking accommodation via the official ...organised jointly by the European Organisation for...onal Cancer Institute and the American Association...
...trial of a catheter-based treatment for deep vein ... drugs in combination with clot removal devices to... DVT (the formation of a blood clot in a leg vein)...causes permanent damage to the veins, resulting in...and/or skin ulcers. About 25�� perce...
Other Biology News:Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results 2Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results 3Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results 4Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 3
Mouse Anti-Hamartin Monoclonal Antibody, Unconjugated, Clone 1B2 from Cell Signaling Technology
Blank Calibration Particles, 3.0-3.4 mu m from BD Biosciences Pharmingen
Rabbit Anti-Human SYT16 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Anti-IL-12 / IL-23 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone C17.8 from eBioscience
Biology Products: